Novartis radioligand triumphs in a first-line PhIII trial recruiting patients with rare neuroendocrine tumors
Novartis’ radioligand therapy Lutathera has hit the primary endpoint in a Phase III trial in newly diagnosed patients with a rare form of neuroendocrine tumors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
